About

Molecular Cancer promotes the exchange of ideas, concepts and findings in any area of cancer and related biomedical science, from a molecular point of view. Molecular Cancer is interested in articles from basic, translational and clinical research, opening new avenues for the understanding, prevention, diagnosis and treatment of cancer. Topics of interest include, but are not limited to: cell and tumor biology, angiogenesis, animal models, metastasis, cancer antigens and the immune response to them, cellular signalling and molecular biology, epidemiology, genetic and molecular profiling of cancer and molecular targets, cancer stem cells, DNA damage and repair, cell cycle, apoptosis, molecular virology and vaccine- and antibody-based cancer therapies.

Molecular Cancer provides an important forum for exciting findings in cancer-related research, presenting an unparalleled opportunity to communicate information to specialists and the public. The online appearance of Molecular Cancer allows the immediate publication of accepted articles and the presentation of large amounts of data and supplemental information to ensure that new research is disseminated as efficiently and quickly as possible to the scientific community.

• Ranked in the top 5% in the Oncology category of the Journal Citation Report, we are an important forum for the developments of cancer-related research.
• We welcome articles in both molecular and clinical aspects of cancer research, offering a high visibility platform for your research, with over 70,000 articles views a month.  
• Our editorial team leads a rigorous and rapid peer review process.
• As a fully open access publication, we ensure that your article can be easily discovered, accessed, used and shared, maximising your impact as an author and acting as a springboard for further discovery.

All articles published by Molecular Cancer are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.

As authors of articles published in Molecular Cancer you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the BMC license agreement.

For those of you who are US government employees or are prevented from being copyright holders for similar reasons, BMC can accommodate non-standard copyright lines. Please contact us if further information is needed.

Authors who publish open access in Molecular Cancer are required to pay an article processing charge (APC). The APC price will be determined from the date on which the article is accepted for publication.

The current APC, subject to VAT or local taxes where applicable, is: £3490.00/$4890.00/€3990.00

Visit our open access support portal and our Journal Pricing FAQs for further information.

For information about the APC applicable for articles accepted for publication next year, please see our journal lists.

Open access funding

Visit Springer Nature’s open access funding & support services for information about research funders and institutions that provide funding for APCs.

Springer Nature offers agreements that enable institutions to cover open access publishing costs. Learn more about our open access agreements to check your eligibility and discover whether this journal is included.

Springer Nature offers APC waivers and discounts for articles published in our fully open access journals whose corresponding authors are based in the world’s lowest income countries (see our APC waivers and discounts policy for further information). Requests for APC waivers and discounts from other authors will be considered on a case-by-case basis, and may be granted in cases of financial need (see our open access policies for journals for more information). All applications for discretionary APC waivers and discounts should be made at the point of manuscript submission; requests made during the review process or after acceptance are unable to be considered.

All articles published in Molecular Cancer are included in:

• Biological Abstracts
• BIOSIS
• CAS
• Citebase
• Current contents
• DOAJ
• Embase
• EmBiology
• MEDLINE
• OAIster
• PubMed
• PubMed Central
• Science Citation Index Expanded
• SCImago
• Scopus
• SOCOLAR
• Zetoc

The full text of all articles is deposited in digital archives around the world to guarantee long-term digital preservation. You can also access all articles published by BioMed Central on SpringerLink.

All manuscripts submitted to Molecular Cancer should adhere to BioMed Central's editorial policies.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors who wish to appeal a rejection or make a complaint should follow the procedure outlined in the BMC Editorial Policies.

Articles in Molecular Cancer should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.

Article citations follow this format:

Authors: Title. Mol Cancer [year], [volume number]:[article number].

e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Mol Cancer 2009, 1:115.

High visibility

Molecular Cancer's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience. 

Speed of publication

Molecular Cancer offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF.

Flexibility

Online publication in Molecular Cancer gives you the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).

Promotion and press coverage

Articles published in Molecular Cancer are included in article alerts and regular email updates. Some may be highlighted on Molecular Cancer’s pages and on the BMC homepage.

In addition, articles published in Molecular Cancer may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Molecular Cancer. A list of articles recently press-released by journals published by BMC is available here.

Copyright

As an author of an article published in Molecular Cancer you retain the copyright of your article and you are free to reproduce and disseminate your work (for further details, see the BMC license agreement).

For further information about the advantages of publishing in a journal from BMC, please click here.